Navigation Links
Molecular profiling can accurately predict survival in colon cancer patients
Date:9/25/2007

ver three times (3.2) more likely to develop metastases than the patients in the good outcome group. This method of identifying poor outcome patients was better at predicting which patients should have adjuvant chemotherapy than the commonly-used method that follows recommendations from the American Society of Clinical Oncology (ASCO).

The researchers checked their findings against information from another set of colon cancer patients that had been published in the Journal of Clinical Oncology in 2005. Prof Tollenaar said: In these stage II colon cancer patients, the five-year metastasis-free survival prediction was confirmed; for the good outcome group, five-year survival was 90% and for the poor outcome group it was 40%. This was important validation of our own results.

From the genome-wide analysis, the researchers identified a subset of 100 genes that were able to predict outcome equally as well as the full-genome molecular expression profile. Many of these genes are know to regulate the Epithelial-Mesenchymal transition (EMT) a programme of cell development that is thought to be a driving force behind the development of metastases in colorectal cancer.

Prof Tollenaar said that although his research predicted outcome of disease in patients who had not received adjuvant chemotherapy, more work would need to be done to identify the molecular profile for those patients who would actually benefit from chemotherapy.

Before the results of this research could start to be used in the clinic, Prof Tollenaar said two things needed to happen: Current, ongoing validation studies required to confirm our findings have to be completed, and the test needs to be developed into a robust diagnostic device. The molecular profiling company Agendia BV of Amsterdam has taken this up and it is likely to be available in early 2008.

As to whether these findings would save large numbers of colon cancer patients from unnecessary chemotherapy,
'/>"/>

Contact: Emma Mason
wordmason@mac.com
34-932-308-834
ECCO-the European CanCer Conference
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Molecular markers for early diagnosis of breast and ovarian cancer
2. Scientists Developed Map For Brain Molecular Communities
3. Molecular Mechanism Of HIV Infecting The Healthy Cells Discovered.
4. Molecular Flaw Detected in Aggressive Breast Cancers
5. Molecular Computer Developed To perform Calculations From Within Human Body
6. Lung cancer molecular profile discovered by researchers.
7. Molecular Imaging Of Cancer Now Possible, New Hybrid Virus Produced
8. Molecular Basis Of ALS Found
9. New Molecular Treatment Identified To Treat Blood Cell Cancers
10. Researchers Find Molecular "Brake" to Cell Death
11. Solitons Could Power Molecular Electronics, Artificial Muscles

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)... , , PEMBROKE, Bermuda, Dec. 4 /PRN...ny Holdings, Ltd (NYSE: AWH ) today announced th...Officer, and Jack Sennott, Executive Vice,Presiden...esenting at the 2009,Goldman Sachs U.S. Financial ...s Conference Center in New York City on Tuesday, D...
(Date:12/4/2009)... , , MADISON HEIGHTS, Mich., Dec...urities Review Committee of BetterInvesting Magaz... ) as its February 2010 "Stock to Study" and C.R....Undervalued Stock" for investors, informational an...rgan because of growth opportunities involving its...
(Date:12/4/2009)... , Late recurrence is a risk for some pediatric c...the central nervous system, according to a new stu...the National Cancer Institute . , This study was...ate recurrence (after 5 years and up to 20 years) ...i-Masker, M.D., of the Aflac Cancer Center and Blo...
(Date:12/4/2009)... , More than 15 million Americans are recruited...ing to the Alliance for Human Research Protection ...ticipation. , Research institutions view pay...xpenses; not as compensation for potential risks r... new study finds that volunteers have a very diffe...
(Date:12/4/2009)... Increasing exercise, water and fruit consumptio...IDAY, Dec. 4 (HealthDay News) -- Increased exercis...among the most effective weight control strategies...ers surveyed 130 adolescents about their weight-co...ad succeeded in losing weight and 68 had not. The ...
Breaking Medicine News(10 mins):Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2Health News:Human guinea pigs wary of high-paying medical trials 2Health News:Teens Lose More Weight Using Healthy Strategies 2
...genital Heart Disease published recently in the Eu...ty of adult heart care and the extent of its defic...improvement in the treatment of pediatric heart di...of the patients and list the deficient areas. 71 c...
... by researchers at Columbia University Medical Cen... rates and adherence to cancer treatment, //it has...had stopped their chemotherapy. More specifically,...efore completion. Non-compliance rates in th...
...rs at University of Manchester now reveals that sp...iseases, Vascular Dementia and Alzheimer's disease...sh Medical Journal (BMJ). This finding could e...d vascular dementia can account for a major propor...
...n 2004 the sales of Celebrex was $3.3 billion worl...g causing heart attacks the company stopped advert...he consumer ad market in hopes of reviving sales o...oost it sales. Each ad includes a boldface warnin...
...quently among children. It is one of the diseases ...ow 3 months of age//. Hence Dr. Lawrence S. Eichen...an Diego and colleagues came up with the fluticaso...en compared to ointments and creams. It is very he...
...ssion of senile amyloidosis to offspring from affe...om mother to child// have been raised. Details abo...is in offspring of mice with AApoAII amyloidosis,'...including amyloidosis. Amyloidosis occurs when cel...
Other Medicine News:Health News:Colon Cancer Death Rate Doubles As Patients Stop Chemotherapy 2Health News:Doubts About In UteroTransmission Of Senile Amyloidosis 2
(Date:12/3/2009)...DOYLESTOWN, Pa., Dec. 3 ...ation, (Nasdaq: QGLY ) www.quigleyco.com announ...ation of its opportunities to develop prescription... that it is in its best interests to focus primari... include but are not limited to its Cold-EEZE®...
(Date:12/3/2009)..., WARRENDALE, Pa., Dec. 3 Radiol... injection-record integration capabilities at the ...n Chicago. The Connect.PACS(TM) product, enabli... its kind, is the latest release in the company,s ... ,, (Photo: http://www.newscom.com/cgi-bin/...
(Date:12/3/2009)..., HOERSHOLM, Denmark and SAN DIEGO, Californi... Successfully Inhibits miR-122, a microRNA Importa...ificantly Reducing Hepatitis C,Virus in the Bloods...,Hepatitis C Virus , - SPC3649 Demonstrat...nd,No Serious Adverse Events in the Treated Animal...
Breaking Medicine Technology:Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 2Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 3MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 2MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 2New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 3New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 4New Data Shows Breakthrough microRNA-Targeted Therapy Developed Using Santaris Pharma A/S Proprietary LNA Technology Holds Promise as New Treatment for Hepatitis C 5Cancer Treatment Centers of America 28R 29 Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells 4608 1Cancer Treatment Centers of America 28R 29 Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells 4608 2Cancer Treatment Centers of America 28R 29 Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells 4608 3Cancer Treatment Centers of America 28R 29 Studies Treatment That Aims Chemotherapy Directly at Ovarian Cancer Cells 4608 4Genes May Raise Risk of Neuroblastoma in Kids 49265 1Genes May Raise Risk of Neuroblastoma in Kids 49265 2Genes May Raise Risk of Neuroblastoma in Kids 49265 3Berlin Heart Inc Receives FDA Orphan Product Development Grant 12679 1Berlin Heart Inc Receives FDA Orphan Product Development Grant 12679 2
...AL GABLES, Fla., Jan. 9 Catalyst,Pharmaceutical P...al company that,acquires, in-licenses, develops an...ent of drug addiction, announced today that it has...e II trial evaluating CPP-109 for the treatment,of...ormulation of vigabatrin,being developed as a trea...
... Switzerland, Jan. 9 ESBATech AG, a leading develo...nced the initiation of the Phase I/IIa clinical de...ESBA105 in osteoarthritis (OA). This double-blind,...al study is designed to investigate the safety, to...ed locally via intra-articular administration to p...
Other Medicine Technology:Catalyst Reaches Enrollment Target for its U.S. Phase II Cocaine Trial 2Catalyst Reaches Enrollment Target for its U.S. Phase II Cocaine Trial 3ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity 2ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity 3ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity 4
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
Medicine Products: